Current Report Filing (8-k)
January 06 2022 - 4:17PM
Edgar (US Regulatory)
0001739104
false
0001739104
2022-01-01
2022-01-01
0001739104
us-gaap:CommonStockMember
2022-01-01
2022-01-01
0001739104
elan:TangiblePercentEquityUnitsMember
2022-01-01
2022-01-01
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event
Reported): January 1, 2022
Elanco
Animal Health Incorporated
(Exact name of registrant as specified
in its charter)
Indiana
|
|
001-38661
|
|
82-5497352
|
(State or other jurisdiction
|
|
(Commission
|
|
(I.R.S. Employer
|
of incorporation)
|
|
File Number)
|
|
Identification No.)
|
2500 Innovation Way
Greenfield, Indiana
|
|
46140
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code: (877)
352-6261
Not Applicable
(Former Name or Address, if Changed
Since Last Report)
Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
|
¨
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which
registered
|
Common stock, no par value
|
|
ELAN
|
|
New York Stock Exchange
|
5.00% Tangible Equity Units
|
|
ELAT
|
|
New York Stock Exchange
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
¨ Emerging
growth company
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On October 5, 2021, Elanco Animal Health Incorporated (“Elanco”)
announced that Aaron Schacht, Executive Vice President of Elanco, would transition to a new role leading the potential carve-out of Elanco’s
microbiome R&D platform (the “Microbiome Platform”). On December 31, 2021, Mr. Schacht, and certain other employees
supporting the Microbiome Platform, separated from Elanco as part of the restructuring plan announced by Elanco on November 30, 2021.
Elanco expects to enter into an agreement with an affiliate of Mr. Schacht,
whereby Mr. Schacht will lead an external team responsible for the continuing development of the Microbiome Platform on behalf of
Elanco, as well as continue to advise on the potential carve-out of the Microbiome Platform from Elanco. Under the agreement, Elanco is
expected to pay the entity a service fee of up to $750,000, made in installments through March 31, 2022, which will be used to pay
compensation to Mr. Schacht’s team and related expenses for the development work. Elanco may also pay a contingent fee tied
to the consummation of the carve-out transaction.
In connection with his separation, Elanco entered into a Severance
Agreement and Release of Claims (the “Agreement”) with Mr. Schacht on January 1, 2022, pursuant to which he is entitled
to receive severance benefits under the Elanco Amended and Restated Executive Severance Pay Plan and Summary. These benefits are contingent
upon Mr. Schacht executing a release of claims in favor of Elanco and agreeing to certain other customary post-employment covenants.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Elanco Animal Health Incorporated
|
|
|
Date: January 6, 2022
|
By:
|
/s/ Marcela Kirberger
|
|
|
Name: Marcela Kirberger
|
|
|
Title: Executive Vice President, General
Counsel and Corporate Secretary
|
Elanco Animal Health (NYSE:ELAN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Elanco Animal Health (NYSE:ELAN)
Historical Stock Chart
From Jul 2023 to Jul 2024